

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**


Applicants Docket Number:
ST01023 US CNT

Applicants:
Jesus Benavides, et al

Serial No.
10/786,810

Filing Date:
February 25, 2004

Title of Invention:
Composition of a CB1 Receptor Antagonist and of a Product Which Activates Dopaminergic Neurotransmission in the Brain, the Pharmaceutical Compositions Comprising Them and Their Use in the Treatment of Parkinson's Disease

CERTIFICATE OF TRANSMISSION	
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 746-9195, on 7-26-04	
Date of Deposit	
Printed Name of Person Signing Certificate Maribel Mendez	
Signature	

Total Number of Pages Sent: **8**

Attorney: **Balaram Gupta**

Group Art Unit: **1614**

Examiner: **Not Yet Assigned**

TO: Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

<input type="checkbox"/> Amendment, 37 CFR _____	<input type="checkbox"/> Fee Transmittal
<input type="checkbox"/> Charge deposit account, in duplicate	<input type="checkbox"/> Petition under 37 CFR _____
<input type="checkbox"/> Extension of Time Petition	<input checked="" type="checkbox"/> Other <u>Transmittal Requesting to Correct Filing Receipt (1 pg.)</u>
<input type="checkbox"/> Issue Fee Transmittal & Advance Order	<input checked="" type="checkbox"/> Other <u>Copy of Filing Receipt (2 pgs.)</u>
<input type="checkbox"/> Maintenance Fee Transmittal	<input checked="" type="checkbox"/> Other <u>Corrected Application Data Sheet (4 pgs.)</u>

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
Jesus Benavides, et al

Examiner: Not Yet Assigned

Application No.: 10/786,810

Art Unit: 1614

Filed: February 25, 2004

Title: Composition of a CB1 Receptor Antagonist and
of a Product Which Activates Dopaminergic
Neurotransmission in the Brain, the
Pharmaceutical Compositions Comprising
Them and Their Use in the Treatment of
Parkinson's Disease

CERTIFICATE OF TRANSMISSION
 I hereby certify that this correspondence is being transmitted via
 facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
 VA 22313-1450, at (703) 746-9195, on 7-26-04
 Date of Deposit
 Printed Name of Person Signing Certificate Maribel Mendez
 Signature Maribel Mendez

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop
 Commissioner of Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Attached is a copy of the "marked-up" official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in the Title which reads: "Combination of a CB1 receptor Antagonist and of a product which activatives dopaminergi neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of Parkinson's disease," and should read: "Combination of a CB1 Receptor Antagonist and of a Product Which Activates Dopaminergic Neurotransmission in the Brain, the Pharmaceutical Compositions Comprising Them and Their Use in the Treatment of Parkinson's Disease." **Also enclosed is the updated Application Data Sheet correcting this error under Title of the Invention.** In addition, please also note that the last inventor noted on the filing receipt, "Henin," is a repeat of the third named inventor, and therefore, should be deleted.

The Commissioner is hereby authorized to charge any fees, which are required by this paper to Deposit Account 18-1982.

Respectfully submitted,

July 26, 2004Balaram Gupta

Balaram Gupta, Reg. No. 40,009
 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, NJ 08807-0800
 Telephone (908) 231-3364
 Telefax (908) 231-2626
 Aventis Docket No. ST01023 US CNT



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS 9004
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov DEPT.

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/786,810	02/25/2004	1614	1188	ST01023 US CNT		36	

005487
ROSS J. OEHLER
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807

UPDATED FILING RECEIPT



10C20000001310223

COMPUTER ENTERED

Yes 7/13/04

Date Mailed: 07/09/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jesus Benavides, Chatenay Malabry, FRANCE;
Daniel Boccio, Fay P. Bippov, FRANCE;
Yvette Henin, Paris, FRANCE;
Odile Piot-Grosjean, Choisy Le Roi, FRANCE;
Henin, Paris, FRANCE; *repeated*

Assignment For Published Patent Application

Aventis Pharma S.A., Cedex, FRANCE;

Domestic Priority data as claimed by applicant

This application is a CON of PCT/FR02/02946 08/28/2002

Foreign Applications


FRANCE 0111200 08/29/2001

If Required, Foreign Filing License Granted: 05/17/2004

Projected Publication Date: 10/21/2004

Non-Publication Request: No

Early Publication Request: No

**Title**

Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 8 months from the filing date of the application. If 8 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).